Study identifies new molecular target for cancer therapy

Researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) have identified a new molecular drug target that could result in new cancer drugs with fewer side effects. Previous studies have shown that vascular endothelial growth factor-A (VEGF-A) ­- a potent cytokine (signaling protein) - and dopamine (a neurotransmitter/neurohormone) ­­play essential roles in many physiological and pathological functions.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news